A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting.
A consensus statement on the European Society for Clinical an Economic Aspects od Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis..pdf
[en] The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014,which provides practical guidance for the prioritization of interventions. Further analysis of real-world data for OA provides additional evidence in support of pharmacological interventions,in terms of management of OA pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes, e.g., delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare
resource utilization. This article provides an updated assessment of the literature for selected
interventions in OA, focusing on real-life data, with the aim of providing easy-to-follow advice on how to establish a treatment flow in patients with knee OA in primary care clinical practice, in support of the clinicians’ individualized assessment of the patient. In step 1, background maintenance therapy with symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) is recommended, for which high-quality evidence is provided only for the prescription formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. Paracetamol may be added for rescue analgesia only,due to limited efficacy and increasing safety signals. Topical non-steroidal anti-inflammatory drugs (NSAIDs) may provide additional
symptomatic treatment with the same degree of efficacy as oral NSAIDs without the systemic safety concerns. Oral NSAIDs maintain a central role in step2 Advanced management of persistent symptoms.
However, oral NSAIDs are highly heterogeneous in terms of gastrointestinal and cardiovascular safety profile, and patient stratification with careful treatment selection is advocated to maximize the risk: benefit ratio. Intra-articular hyaluronic acid as a next step provides sustained clinical benefit with effects lasting up to 6 months after a short-course of weekly injections. As a last step before surgery, thes low titration of sustained-release tramadol, aweak opioid, affords sustained analgesia with improved tolerability.
Disciplines :
General & internal medicine
Author, co-author :
Bruyère, Olivier ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cooper, C.
Pelletier, J.P.
Maheu, E.
Rannou, F.
Branco, J.
Brandi, M.L.
Kanis, J.A.
Altman, R.D.
Hochberg, M.C.
Martel-Pelletier, J.
Reginster, Jean-Yves ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting.
Publication date :
2016
Journal title :
Seminars in Arthritis and Rheumatism
ISSN :
0049-0172
eISSN :
1532-866X
Publisher :
W.B. Saunders, Philadelphia, United States - Pennsylvania
Woolf A.D., Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003, 81:646-656.
Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
White A.G., Birnbaum H.G., Janagap C., Buteau S., Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med 2008, 50:998-1005.
Bruyere O., Cooper C., Pelletier J.P., Branco J., Brandi M.L., Guillemin F., et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014, 44:253-263.
Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012, 64:465-474.
McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014, 22:363-388.
National Clinical Guideline Centre. Osteoarthritis care and management in adults: methods, evidence and recommendations. London, UK: National Institute for Health and Care Excellence; February 2014. Report No.: CG177.
Bruyere O., Altman R.D., Reginster J.-Y. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016, 45(Suppl.):S12-S17.
Rannou F., Pelletier J.-P., Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016, 45(Suppl.):S18-S21.
Pelletier J.-P., Martel-Pelletier J., Rannou F., Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016, 45(Suppl.):S22-S27.
Maheu E., Rannou F., Reginster J.-Y. Efficacy and safety of hyaluronic acid in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016, 45(Suppl.):S28-S33.
Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
FDA. Drug Safety Communication 13 January 2011: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. ; 2011 [accessed 01.06.15]. http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm.
Rahme E., Barkun A., Nedjar H., Gaugris S., Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008, 103:872-882.
Curhan G.C., Knight E.L., Rosner B., Hankinson S.E., Stampfer M.J. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004, 164:1519-1524.
Curhan G.C., Willett W.C., Rosner B., Stampfer M.J. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002, 162:2204-2208.
Forman J.P., Rimm E.B., Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007, 167:394-399.
Martel-Pelletier J., Pelletier J.P. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010, 2:95-104.
Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001, 44:2539-2547.
Maheu E., Mazieres B., Valat J.P., Loyau G., Le Loet X., Bourgeois P., et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998, 41:81-91.
Reginster J.Y. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007, 56:2105-2110.
Eriksen P., Bartels E.M., Altman R.D., Bliddal H., Juhl C., Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res 2014, 66:1844-1855.
Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
De Wan M, Volpi G inventors; Rottapharm, assignee. Method of preparing mixed glucosamine salts. USA patent 5,847,107. 1998.
Herrero-Beaumont G., Ivorra J.A., Del Carmen Trabado M., Blanco F.J., Benito P., Martin-Mola E., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56:555-567.
Bjordal J.M., Ljunggren A.E., Klovning A., Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. Br Med J 2004, 329:1317.
Cooper C., Adachi J.D., Bardin T., Berenbaum F., Flamion B., Jonsson H., et al. How to define responders in osteoarthritis. Curr Med Res Opin 2013, 29:719-729.
Bruyere O., Pavelka K., Rovati L.C., Gatterova J., Giacovelli G., Olejarova M., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008, 16:254-260.
Rovati L.C., Girolami F., D'Amato M., Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 2016, 45(Suppl.):S34-S41.
Scholtissen S., Bruyere O., Neuprez A., Severens J.L., Herrero-Beaumont G., Rovati L., et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010, 64:756-762.
Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008, 24:3029-3035.
Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011, 70:982-989.
Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
Zegels B., Crozes P., Uebelhart D., Bruyere O., Reginster J.Y. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage 2013, 21:22-27.
Hochberg M., Chevalier X., Henrotin Y., Hunter D.J., Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?. Curr Med Res Opin 2013, 29:259-267.
Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
Hochberg M.C., Martel-Pelletier J., Monfort J., Moller I., Castillo J.R., Arden N., et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016, 75:37-44. 10.1136/annrheumdis-2014-206792.
Houpt J.B., McMillan R., Wein C., Paget-Dellio S.D. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999, 26:2423-2430.
Fransen M., Agaliotis M., Nairn L., Votrubec M., Bridgett L., Su S., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2015, 74:851-858.
Martel-Pelletier J., Roubille C., Abram F., Hochberg M.C., Dorais M., Delorme P., et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015, 74:547-556.
Gallagher B., Tjoumakaris F.P., Harwood M.I., Good R.P., Ciccotti M.G., Freedman K.B. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med 2015, 43:734-744.
Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Rockville MD; October 2011. ; [accessed 01.06.15]. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016485/pdf/TOC.pdf.
Lin J., Zhang W., Jones A., Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. Br Med J 2004, 329:324.
Tugwell P.S., Wells G.A., Shainhouse J.Z. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004, 31:2002-2012.
Simon L.S., Grierson L.M., Naseer Z., Bookman A.A., Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009, 143:238-245.
Derry S., Moore R.A., Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012, 9:CD007400.
Rother M., Conaghan P.G. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol 2013, 40:1742-1748.
Conaghan P.G., Dickson J., Bolten W., Cevc G., Rother M. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 2013, 52:1303-1312.
Rechziegler H. Perkutane Therapie mit nicht-steroidalen Antiphlogistika. Therapiewoche 1986, 36:4674-4683.
Walde HJ. Konzentration von Etofenamat in intra- und periartikulären Geweben nach perkutaner Applikation beim Menschen. Topische Behandlung mit nichtsteroidalen Antirheumatika. 4. Int. Etofenamat-Symposium vom 18.-21.6. 1987 in Stresa, Italien: pmi-Verlag Frankfurt/Main, Der neue Weg; 1987. p. S91-4.
Efe T., Sagnak E., Roessler P.P., Getgood A., Patzer T., Fuchs-Winkelmann S., et al. Penetration of topical diclofenac sodium 4% spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. Knee Surg Sports Traumatol Arthrosc 2014, 22:345-350.
Underwood M., Ashby D., Cross P., Hennessy E., Letley L., Martin J., et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. Br Med J 2008, 336:138-142.
Blumberger W. Einsparung oraler Antirheumatika durch lokale Anwendung von Etofenamat Gel. Therapiewoche 1980, 30:4949-4954.
Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., et al. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
Henry D., McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract 2003, 135(Suppl.):43-49.
Garcia Rodriguez L.A., Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001, 3:98-101.
Hunt R.H., Barkun A.N., Baron D., Bombardier C., Bursey F.R., Marshall J.R., et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002, 16:231-240.
Masso Gonzalez E.L., Patrignani P., Tacconelli S., Garcia Rodriguez L.A. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010, 62:1592-1601.
Chou C.T., Tsai Y.Y. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res 2002, 12:1-6.
Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C., Fourrier-Reglat A., Nicotra F., et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012, 35:1127-1146.
Freston J.W. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 1999, 107:78 S-88 S.
Lipani J.A., Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995, 3:351-361.
Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2037-2046.
Bhala N., Emberson J., Merhi A., Abramson S., Arber N., Baron J.A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, 382:769-779.
Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000, 7:115-121.
Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007, 369:1621-1626.
FDA. Information for healthcare professionals: Concomitant use of ibuprofen and aspirin. ; 2006 [accessed 01.06.15]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222.htm.
Olsen A.M., Fosbol E.L., Lindhardsen J., Folke F., Charlot M., Selmer C., et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation 2012, 126:1955-1963.
Bellamy N., Campbell J., Robinson V., Gee T., Bourne R., Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005321.
Bannuru R.R., Schmid C.H., Kent D.M., Vaysbrot E.E., Wong J.B., McAlindon T.E. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015, 162:46-54.
Zhang R.X., Ren K., Dubner R. Osteoarthritis pain mechanisms: basic studies in animal models. Osteoarthritis Cartilage 2013, 21:1308-1315.
Bannuru R.R., Vaysbrot E.E., Sullivan M.C., McAlindon T.E. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2014, 43:593-599.
Miller L.E., Block J.E. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. Clin Med Insights Arthritis Musculoskelet Disord 2013, 6:57-63.
Bannuru R.R., Natov N.S., Obadan I.E., Price L.L., Schmid C.H., McAlindon T.E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009, 61:1704-1711.
Navarro-Sarabia F., Coronel P., Collantes E., Navarro F.J., de la Serna A.R., Naranjo A., et al. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis 2011, 70:1957-1962.
Petrella R.J. Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil 2005, 84:278-283.
Waddell D.D., Bricker D.C. Clinical experience with the effectiveness and tolerability of hylan G-20 in 1047 patients with osteoarthritis of the knee. J Knee Surg 2006, 19:19-27.
Kausch R., Lahne U., Thomas R., Kipshoven C., Schuld M. Intrarticular hyaluronic acid in the treatment of arthroses. Orthopädische Praxis 2009, 45:258-266.
Abbott T., Altman R.D., Dimef R., Fredericson M., Vad V., Vitanzo P.J. Do hyaluronic acid injections delay total knee replacement surgery?. Arthritis Rheum 2013, 65(Suppl. 1):S910-S911.
Waddell D.D., Bricker D.C. Total knee replacement delayed with Hylan G-20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007, 13:113-121.
Mar J., Romero Jurado M., Arrospide A., Enrique Fidalgo A., Soler Lopez B. Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis. Rev Esp Cir Ortop Traumatol 2013, 57:6-14.
Karlsson J., Sjogren L.S., Lohmander L.S. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002, 41:1240-1248.
Kirchner M., Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006, 14:154-162.
Juni P., Reichenbach S., Trelle S., Tschannen B., Wandel S., Jordi B., et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007, 56:3610-3619.
Pavelka K., Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(R) vs hylan G-F20 [Synvisc(R)]) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage 2011, 19:1294-1300.
Maheu E., Zaim M., Appelboom T., Jeka S., Trc T., Berenbaum F., et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol 2011, 29:527-535.
Berenbaum F., Grifka J., Cazzaniga S., D'Amato M., Giacovelli G., Chevalier X., et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis 2012, 71:1454-1460.
Reichenbach S., Blank S., Rutjes A.W., Shang A., King E.A., Dieppe P.A., et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007, 57:1410-1418.
Chen A.L., Desai P., Adler E.M., Di Cesare P.E. Granulomatous inflammation after Hylan G-20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 2002, 84-A:1142-1147.
Bagga H., Burkhardt D., Sambrook P., March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 2006, 33:946-950.
Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent?. Semin Arthritis Rheum 2002, 32:10-37.
Pozo M.A., Balazs E.A., Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997, 116:3-9.
Smith M.M., Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987, 7:113-122.
Diaz-Gallego L., Prieto J.G., Coronel P., Gamazo L.E., Gimeno M., Alvarez A.I. Apoptosis and nitric oxide in an experimental model of osteoarthritis in rabbit after hyaluronic acid treatment. J Orthop Res 2005, 23:1370-1376.
Aviad A.D., Houpt J.B. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it?. J Rheumatol 1994, 21:297-301.
Solomon D.H., Rassen J.A., Glynn R.J., Lee J., Levin R., Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010, 170:1968-1976.
Hochberg M.C., Wohlreich M., Gaynor P., Hanna S., Risser R. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012, 39:352-358.
Risser R.C., Hochberg M.C., Gaynor P.J., D'Souza D.N., Frakes E.P. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage 2013, 21:691-694.
Cepeda M.S., Camargo F., Zea C., Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006, 3:CD005522.
Roth S.H. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998, 25:1358-1363.
Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43:879-923.
Langley P.C., Patkar A.D., Boswell K.A., Benson C.J., Schein J.R. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin 2010, 26:239-251.
Gana T.J., Pascual M.L., Fleming R.R., Schein J.R., Janagap C.C., Xiang J., et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006, 22:1391-1401.
Raber M., Schulz H.U., Schurer M., Krupp S., Momberger H. Pharmacokinetic properties of tramadol sustained release capsules. 3rd communication: investigation of relative bioavailability under steady state conditions. Arzneimittelforschung 1999, 49:594-598.
Cnota P.J., Nowak H., Tagarro I., Erb K., Schurer M., Schulz H.U., et al. Tramadol SR formulations: pharmacokinetic comparison of a multiple-units dose (capsule) versus a single-unit dose (tablet). Clin Drug Investig 2005, 25:435-443.
Tagarro I., Herrera J., Barutell C., Diez M.C., Marin M., Samper D., et al. Effect of a simple dose-escalation schedule on tramadol tolerability: assessment in the clinical setting. Clin Drug Investig 2005, 25:23-31.
Bruyere O., Cooper C., Arden N., Branco J., Brandi M.L., Herrero-Beaumont G., et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging 2015, 32:179-187.
